Natera, Inc. (NASDAQ:NTRA) Shares Sold by Teacher Retirement System of Texas

Teacher Retirement System of Texas decreased its stake in shares of Natera, Inc. (NASDAQ:NTRA - Free Report) by 58.0% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 18,335 shares of the medical research company's stock after selling 25,358 shares during the quarter. Teacher Retirement System of Texas' holdings in Natera were worth $2,593,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Fulton Bank N.A. increased its holdings in shares of Natera by 2.0% in the first quarter. Fulton Bank N.A. now owns 3,652 shares of the medical research company's stock valued at $516,000 after purchasing an additional 71 shares during the period. QRG Capital Management Inc. boosted its position in Natera by 1.5% in the first quarter. QRG Capital Management Inc. now owns 5,417 shares of the medical research company's stock valued at $766,000 after buying an additional 81 shares during the last quarter. Colonial Trust Co SC increased its holdings in Natera by 7.8% in the 4th quarter. Colonial Trust Co SC now owns 1,325 shares of the medical research company's stock worth $210,000 after buying an additional 96 shares during the period. Silvercrest Asset Management Group LLC raised its position in Natera by 3.6% during the 4th quarter. Silvercrest Asset Management Group LLC now owns 2,812 shares of the medical research company's stock worth $445,000 after buying an additional 98 shares during the last quarter. Finally, Utah Retirement Systems boosted its holdings in shares of Natera by 1.6% in the 4th quarter. Utah Retirement Systems now owns 6,200 shares of the medical research company's stock valued at $981,000 after acquiring an additional 100 shares during the last quarter. Hedge funds and other institutional investors own 99.90% of the company's stock.

Wall Street Analyst Weigh In

NTRA has been the subject of several recent research reports. Wall Street Zen cut shares of Natera from a "hold" rating to a "sell" rating in a report on Saturday, May 17th. UBS Group lifted their price objective on Natera from $211.00 to $218.00 and gave the company a "buy" rating in a research note on Friday, May 9th. Piper Sandler raised their target price on Natera from $205.00 to $210.00 and gave the stock an "overweight" rating in a report on Thursday, May 15th. Barclays boosted their price target on Natera from $160.00 to $190.00 and gave the company an "overweight" rating in a report on Friday, May 9th. Finally, Royal Bank Of Canada initiated coverage on shares of Natera in a research note on Thursday, March 13th. They set an "outperform" rating and a $251.00 price objective on the stock. One investment analyst has rated the stock with a sell rating and fifteen have assigned a buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $184.63.

Natera Stock Performance

Shares of NTRA traded up $1.61 during mid-day trading on Thursday, hitting $163.36. 1,156,837 shares of the company were exchanged, compared to its average volume of 1,423,831. The stock has a market cap of $22.31 billion, a price-to-earnings ratio of -111.13 and a beta of 1.73. Natera, Inc. has a 1-year low of $92.14 and a 1-year high of $183.00. The company has a 50 day moving average of $160.74 and a 200-day moving average of $158.45.

Natera (NASDAQ:NTRA - Get Free Report) last announced its earnings results on Thursday, May 8th. The medical research company reported ($0.50) EPS for the quarter, beating analysts' consensus estimates of ($0.59) by $0.09. The business had revenue of $501.83 million during the quarter, compared to analysts' expectations of $446.68 million. Natera had a negative return on equity of 18.29% and a negative net margin of 10.36%. The business's revenue was up 36.5% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($0.56) earnings per share. Research analysts anticipate that Natera, Inc. will post -1.49 earnings per share for the current fiscal year.

Insider Transactions at Natera

In related news, Director Gail Boxer Marcus sold 4,299 shares of the firm's stock in a transaction dated Tuesday, July 1st. The shares were sold at an average price of $167.36, for a total transaction of $719,480.64. Following the completion of the sale, the director directly owned 8,118 shares in the company, valued at approximately $1,358,628.48. This trade represents a 34.62% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Solomon Moshkevich sold 3,000 shares of the business's stock in a transaction dated Monday, June 2nd. The shares were sold at an average price of $157.07, for a total transaction of $471,210.00. Following the completion of the transaction, the insider owned 133,205 shares in the company, valued at $20,922,509.35. The trade was a 2.20% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 53,272 shares of company stock valued at $8,345,368. Corporate insiders own 7.60% of the company's stock.

About Natera

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.